Translational Research Institute

Atrium of the Translational Research Institute

The Translational Research Institute (TRI) is a significant Australian-first initiative in ‘bench to bedside’ medical research. TRI accelerates the transfer of medical research, development into proven treatment.  It is home to a range of cutting edge technologies including interventions to prevent and treat human diseases, and provide diagnosis of early disease.

Supported by grants from the Australian and Queensland Governments, situated in the Princess Alexandra Hospital precinct, TRI combines the research intellect and capability of Queensland Health, The University of Queensland, Queensland University of Technology and the Mater Hospital.

TRI houses over 1,000 leading researchers and support scientists who interface with clinicians on the hospital campus and at other Brisbane-based hospitals. It has two clinical trial facilities, one based at the PA Hospital and the other at the Centre for Children’s Health Research next to the Queensland Children’s Hospital. TRI licences space to six start-up companies and space in an adjacent building to the biopharmaceutical manufacturer Thermo Fisher.

As a Translation Research Institute, TRI is charged with partnering scientific development with the commercial sector to ensure innovations move rapidly to improve patient outcomes and commercial return. To this end, TRI is at the interface of science, medicine and industry.

Innovation Programs

  • Translating Immunotherapy Innovation Program
  • Translating Diagnostic Imaging Innovation Program
  • Translating Microbiome Innovation Program

Research areas

The TRI focuses on a wide range of health and medical research areas including:

  • Tumour Immunology and Immunotherapy
  • Liver Disease
  • Kidney Disease
  • Dermatology
  • Gastroenterology and Hepatology
  • Genomics
  • Metabolomics
  • Mental Health
  • Trauma
  • PTSD
  • Chronic Pain
  • Cancer.

Core Facilities

World-class technology and equipment is available to all researchers through shared specialist core facilities. This highly specialised equipment is also available to external researchers and institutions.

  • Biological Research Facility
  • Gnotobiotic Facility
  • Preclinical Imaging Facility
  • Microscopy Facility
  • Flow Cytometry Facility
  • Proteomics Facility
  • Histology Facility
  • Clinical Trials Facility

Joint venture

The  TRI is a joint venture between the University of Queensland's Diamantina Institute, Queensland University of Technology's Institute of Health and Biomedical Innovation, Mater Research and the Princess Alexandra Hospital.